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Abstract: Fibroblast Growth Factor 23 (FGF23) and Klotho play an essential role in the regulation
of mineral metabolism, and both are altered as a consequence of renal failure. FGF23 increases to
augment phosphaturia, which prevents phosphate accumulation at the early stages of chronic kidney
disease (CKD). This effect of FGF23 requires the presence of Klotho in the renal tubules. However,
Klotho expression is reduced as soon as renal function is starting to fail to generate a state of FGF23
resistance. Changes in these proteins directly affect to other mineral metabolism parameters; they may
affect renal function and can produce damage in other organs such as bone, heart, or vessels. Some of
the mechanisms responsible for the changes in FGF23 and Klotho levels are related to modifications
in the Wnt signaling. This review examines the link between FGF23/Klotho and Wnt/β-catenin in
different organs: kidney, heart, and bone. Activation of the canonical Wnt signaling produces changes
in FGF23 and Klotho and vice versa; therefore, this pathway emerges as a potential therapeutic target
that may help to prevent CKD-associated complications.
Keywords: FGFG23; Klotho; Wnt/b-catenin; CKD; cardiorenal syndrome
Key Contribution: FGF23, Klotho, and the activation of the Wnt/β-catenin pathway play a critical
role in the progression of CKD, but also on different comorbidities associated with CKD such
as cardiovascular disease, cardiac fibrosis, bone frailty among others. The interactions between
FGF23/Klotho axis and Wnt elements could contribute to pathological processes such as renal
hypertension, mineral metabolism alterations, vascular calcification, renal and cardiac fibrosis, cardiac
hyperthrophy or arrhythmias.
1. Introduction
Chronic kidney disease (CKD) causes alterations in mineral metabolism, which worsens as the
renal disease progresses. It is observed that with only a marginal decrease of glomerular filtration,
there is a downregulation of renal α-Klotho (Klotho) [1]. Renal Klotho is the co-receptor of Fibroblast
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Growth Factor Receptor-1 (FGFR1), the specific receptor of the phosphaturic hormone Fibroblast
Growth Factor-23 (FGF23). Thus, FGF23 promotes urinary excretion of phosphate and prevents
hyperphosphatemia until the glomerular filtration rate falls below 15–20 mL/min. In addition to
α-Klotho, expressed in tubular cell membranes, there are two other types of Klotho: soluble (sKlotho)
and secreted Klotho, with additional effects in other organs. Actually, there are studies showing the
pleiotropic effects of Klotho in the cardiovascular system [2], bone [3], and even as a tumor suppressor
molecule [4,5]. The mechanisms behind this reduction of renal α-Klotho during CKD are unclear, and
they are attributed mainly to kidney function deterioration, although Wnt/b-catenin activation has also
been suggested as a key factor leading to Klotho reduction [6].
FGF23 is a hormone produced mainly in mature osteoblasts and osteocytes, and in addition to
its phosphaturic effect, it also inhibits 1,25(OH)2D and PTH production [7]. In CKD patients, the
concentration of plasma FGF23 increases progressively in part due to kidney resistance to the action of
FGF23 generated by the lack of the co-receptor α-Klotho. An experiment in animals demonstrated
that the reduction of α-Klotho is precipitated by an excessive tubular load of phosphate [6,8]. In fact,
the increase in FGF23 levels is accompanied by a marked decrease in Klotho. Drueke et al. showed a
descriptive illustration where it is collected through progressive changes in the parameters of mineral
metabolism, and through CKD parameters during renal disease progression [1]. It is interesting to note
that in parallel to the decrease of Klotho, and the increase of FGF23, there are also changes in the levels
of Wnt inhibitors, such as sclerostin or Dickkopf-related proteins (Dkk1). However, the relationship
between the FGF23/Klotho axis and Wnt signaling has not been sufficiently explored.
Works from different researchers have described an interrelationship between alterations in
mineral metabolism and changes in Wnt signaling in the kidney, vessels, heart, bone, and brain,
among others. This review will summarize the relationship between Wnt signaling, FGF23, and
Klotho expression.
2. The Wnt/β-Catenin Cell Signaling Pathway
The Wnt pathway is highly conserved in the evolution of animal life. It is classified into several
sub-pathways called canonical and non-canonical. The non-canonical Wnt pathways are not dependent
on the β-catenin-T-cell factor/lymphoid enhancer-binding factor (TCF/LEF), such as the Wnt/Ca2+
pathway and the non-canonical Wnt planar cell polarity [9]. The canonical Wnt pathway involves the
nuclear translocation of β-catenin and the activation of the target genes via TCF/LEF transcription
factors (Figure 1). The activation of the canonical Wnt pathway requires the binding of the Wnt ligands
to the receptors of the Frizzled family, and the interaction with co-receptors lipoprotein-receptor related
protein 5 (LRP5) and LRP6. The binding of ligand and receptor stimulates the sequestration of Axin
protein by the Disheveled protein, which prevents the formation of the complex necessary for the
degradation of β-catenin. In this setting, β-catenin is not phosphorylated, became stabilized, and is
translocated into the nucleus. Into the nucleus, it activates the transcription of the Wnt target genes
through the interaction with the transcription factors TCF/LEF [10] (Figure 1A).
In the absence of soluble Wnt protein ligands, the protein Axin forms a complex with the proteins
adenomatous polyposis coli (APC), Casein kinase 1 isoform α (CK1α), and glycogen synthase kinase
3b (GSK3b). Axin and APC act as scaffold proteins for GSK3β that binds and phosphorylates β-catenin,
which is degraded by the proteasome (Figure 1B).
Some proteins regulate the Wnt/β-catenin pathway by blocking the Wnt ligands and co-receptors.
The members of the secreted Frizzled-related protein (sFRP) are proteins that contain a cysteine-rich
domain homologous to the putative Wnt-binding site of Frizzled proteins, which inhibit Wnt activation
(Figure 1B). Other proteins as sclerostin (the product of the SOST gene) and Dkk1 interact with LRP5/6,
and they function as Wnt signaling inhibitors. Sclerostin binds the LRP5/6 receptors, impairs the
LRP5/6-Frizzled interaction, and the interaction of the Wnt signaling proteins with the receptors [11,12].
Dkk1 also binds the LRP5/6 receptor and prevents the activation of the Wnt/β-catenin pathway [13]
(see Figure 1).
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Although there is not much evidence about the direct interaction of FGF23 or Klotho with
Wnt elements, it has been shown that the extracellular domain of Klotho binds to multiple Wnt
ligands, inhibiting their ability to activate Wnt signaling [14,15]. It is also known that there is a
reciprocal relationship between Klotho, FGF23, and Wnt signaling; thus, Wnt signaling dysregulation
affects to FGF23 and Klotho levels and vice versa. There is data suggesting potential crosstalk
between Wnt/β-catenin signaling and the regulation of Klotho and FGF23. In CKD patients, uremic
toxins, phosphate overload, sclerostin, Dkk1, and inflammation may affect Wnt signaling, thus
contributing to the progression of CKD-associated comorbidities [16]. This subject will be exposed in
the following sections.
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Figure 1. Simplified scheme of the Wnt/β-catenin signaling pathway. (A) Wnt ligand interaction with
Frizzled protein and LRP5/6. Disheveled (DVL) protein binds the Frizzled receptor and sequester
the protein complex CK1a-GSK3-Axin-APC blocking β-catenin phosphorylation and degradation.
β-catenin activates TCF/LEF transcription factor in the nucleus. (B) Interference of Wnt ligand–Frizzled
protein interaction by sFRP, SOST, or DKK1. Disheveled (DVL) protein does not bind to the Frizzled
receptor. Protein complex GSK3-Axin-APC phosphorylates β-catenin. Phosphorylated β-catenin is led
to proteasomal degradation. Abbreviations: GSK3b: glycogen synthase kinase 3; APC: adenomatous
polyposis coli; TCF/LEF: T-cell factor/lymphoid enhancer-binding factor; sFRP: secreted Frizzled-related
proteins; SOST: sclerostin; DKK1: Dickkopf-related proteins.
3. Klotho-FGF23 and Wnt in Chronic Kidney Disease
3.1. Regulation of Klotho Expression in the Kidney: The Effect of the Tubular Load of Phosphate
Our group has studied the factors associated with a reduction of renal Klotho expression in rats.
Administration of recombinant FGF23 (rFGF23) produced phosphaturia and reduced renal Klotho
expression in healthy rats [6]. In 5/6 nephrectomized rats, circulating levels of FGF23 were markedly
increased, and Klotho was found to be reduced. In these rats, the administration of anti-FGF23
antibodies further reduced the renal Klotho expression. These results suggest that the increased tubular
load of phosphate causes a reduction in Klotho expression. In vitro, HEK-293 cells incubated in high
phosphate medium produced nuclear translocation of β-catenin that was followed by a reduction in
Klotho expression [6]. We concluded that high phosphate levels decreased renal Klotho expression
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via activation of the Wnt/β-catenin pathway (Figure 2). The administration of calcitriol to cultured
HEK-293 cells prevented Klotho reduction induced by high phosphate.
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Figure 2. Schematic representation of FGF23/Klotho interactions with the Wnt/b-catenin pathway in
the bone, kidney, and heart.
3.2. Klotho, Wnt/β-Catenin, and Renal Damage
Albuminuria downregulates tubular expression of Klotho even in the early stages of CKD [17].
Klotho deficiency induces Wnt activation, which, in turn, is associated with podocyte injury in mice
models of diabetic nephropathy and patients with diabetes [18]. Podocyte injury is reduced after
the deletion of β-catenin [18]. Although not fully elucidated, Snail-1, a transcription factor induced
by Wnt through GSK3b, reduces nephrin expression playing a pivotal role in podocyte injury [19].
The opposite effect is observed with the overexpression of the Wilms Tumor 1 (WT1), which actively
suppresses the Wnt pathway through the inhibition of Disheveled protein in podocytes [20].
In the mature kidney, Wnt is suppressed, allowing the podocyte to perform its physiological
function. Interestingly, Wnt/β-catenin activity may be affected by high glucose; thus, a pathogenic
role of Wnt/β-catenin in diabetic nephropathy cannot be ruled out [21]. In this regard, in a mice
model of diabetic nephropathy, Klotho seems to protect glomerular and podocyte injury by inhibiting
glomerular hypertrophy and reducing albuminuria [22]. Klotho may also reduce proteinuria by
blocking the transient receptor potential cation channel (TRPC6) in podocytes [23], and in the heart,
Klotho attenuates stress-induced cardiac hypertrophy via inhibition of TRPC6 [24].
3.3. Klotho, Wnt/β-Catenin, and Polycystic Kidney Disease (PKD)
The Wnt/β-catenin pathway activation is also involved in the development of polycystic kidney
disease (ADPKD) [25,26]. These patients show increased plasma levels of FGF23 as compared to
GFR-matched CKD patients or healthy volunteers irrespective of the renal function, age, and serum
levels of PTH and vitamin D [27]. Furthermore, ADPKD patients exhibit resistance to the renal
effect of FGF23 that could be explained by the reduction in Klotho [28]. ADPKD patients show
significantly reduced circulating sKlotho, as well as higher FGF23 with a superior FGF23-to-Klotho
ratio as compared to healthy volunteers and GFR-matched CKD 1 and 2 patients [28]. Interestingly,
sKlotho levels inversely correlate with the total cyst volume and the annual growth of the kidney.
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Cardiovascular disease (CVD) is apparent in ADPKD patients. Indeed, a high incidence of
intracranial aneurysms, mitral and aortic valvular prolapse, aortic regurgitation, left ventricular
hypertrophy (LVH), and coronary artery disease has been reported, all of which may culminate in
heart failure (HF) [29–31]. Although some of these manifestations have a genetic background, such as
aneurysms, it is also possible that the dysregulation of the FGF23–Klotho complex could play a role
in the development of these complications, mainly those that directly affect the heart. However, to
our knowledge, no study has described crosstalk between FGF23 increase and Klotho reduction as
responsible for ADPKD cardiac and vascular disease.
3.4. Consequences of the Close Relationship between Wnt and Klotho
Since Klotho is downregulated in CKD, it is important to delineate this relationship. The fall of
renal Klotho is postulated as one of the most important effects of Wnt signaling activation. Therefore,
the design of new strategies directed to increase Klotho levels should be considered as a strategy to
reduce morbidity and mortality associated with kidney and heart diseases.
sKlotho binds to multiple Wnt ligands suppressing a variety of gene transcription.
The upregulation of Klotho halts the activation of Wnt, which reduces the deposition of the extracellular
matrix and decreases the transcription of cytokines [32]. The contrary is observed in Klotho heterozygous
mutant mice in which Wnt is overexpressed together with an increment of Transforming Growth
Factor-β (TGF-β) and collagen type III (Col3); the extracellular matrix deposition and interstitial fibrosis
are remarkable as compared to the wild type. Hence, in vivo models have demonstrated that sKlotho
attenuates renal fibrosis by halting Wnt signaling [33].
3.5. Kidney Fibrosis
Recently, the Wnt pathway in the kidney has gained attention because of its association with renal
fibrosis. In the kidney, pericytes are recognized as collagen-producing cells [34]. Once a kidney injury
is established, pericytes migrate to the interstitial space where they differentiate into scar-forming
myofibroblasts [34]. In this context, the Wnt pathway is markedly activated in pericytes at the time
they differentiate into myofibroblasts, which may cause fibrosis of the kidney interstitium [35].
3.6. Cardiorenal Syndrome
Cardiorenal syndromes have been defined as “disorders of the heart and kidneys whereby acute or
chronic dysfunction in one organ may induce acute or chronic dysfunction of the other [36]. There are
five subcategories of cardiorenal syndrome based on the primary damaged organ (heart or kidney) and
the time course of progression (acute or chronic) [36]. Type 2 cardiorenal syndrome (CRS2) is where HF
causes renal dysfunction, and type 4 CRS (CRS4) is where advanced CKD promotes heart dysfunction.
With respect to CRS4, clinical reports have substantiated a relationship between heart and kidney
disease [37]. It appears that Klotho deficiency may contribute to the generation of cardiac hypertrophy
observed in patients CKD stages G3a–b and G4; however, publications on this issue are limited [38].
In the case of CRS2, a study on a mice model of HF has shed light on the potential mechanisms
connecting cardiac and renal dysfunction [39]. In these mice, the constriction of the aorta induced LVH
and HF. The increased cardiac remodeling was associated with a significant reduction of Klotho and
activation of the Wnt/β-catenin and renin–angiotensin system (RAS). The Wnt/β-catenin activation
mediates the injury in both organs, heart, and kidney. Once HF is established, the renal expression
of podocalyxin was reduced while fibronectin and Snail1 expression increased, resulting in kidney
interstitial fibrosis and albuminuria [39].
Furthermore, different cardiac Wnt ligands increased together with β-catenin, angiotensin-
converting enzyme (ACE), renin, and angiotensin I (AT1) expression. Perhaps, the most important
finding of this research is that the inhibition of the cardiac-secreted Wnt/β-catenin/RAS axis prevented
kidney injury by a downregulation of the expression of fibronectin, Snail1, ACE, renin, and AT1 in the
kidney with a consequent reduction of kidney interstitial fibrosis. All the cardiac lesions worsened
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in association with renal-dependent Klotho depletion. The presence of sKlotho partially inhibited
Wnt/β-catenin signaling, which in turn promoted the downregulation of cardiac fibronectin and
α-smooth muscle actin. Therefore, the activity of Wnt/β-catenin in the heart is accompanied by kidney
injury. Concomitantly, Klotho deficiency resulting from kidney failure worsens cardiac remodeling and
function. This finding is not surprising since Klotho deficiency, high serum phosphate, and elevated
FGF23 have been demonstrated to modulate cardiac remodeling [40] (Figure 2).
In CKD patients, more information on the relationship between serum Klotho and FGF23 levels
and the values of the Wnt ligands, such as Wnt1, Wnt3a, or Wnt10b, could be useful to assess the
comorbidities dependent on the Wnt signaling system, such as renal and cardiac fibrosis.
4. FGF23/Klotho/Wnt in Cardiovascular Disease (CVD)
The involvement of Wnt signaling activation in the pathogenesis of CVD has been widely
documented. In addition to the cardiovascular development during embryogenesis, Wnt signaling
participates in many cardiac and vascular pathological processes such as RAS alterations, cardiac
fibrosis and hypertrophy, atherosclerosis, vascular calcification, endothelial dysfunction, myocardial
infarction, or arrhythmias [41] (Figure 2).
4.1. Klotho, Wnt/β-Catenin, and RAS
Another point of interest is the association between Wnt/β-catenin signaling and the Pro-Renin
Receptor (PRR), a component of the RAS, and critical regulator of blood pressure [42]. In the kidney,
PRR is involved in nephron formation, podocytes instability, blood pressure regulation, and sodium
transport [42,43]. PRR increases as CKD progress; however, the mechanisms leading are not fully
understood. A recent study has demonstrated that Wnt/β-catenin stimulates PRR mRNA expression
of in a dose-dependent manner [42]. Similarly, PRR overexpression triggers Wnt gene transcription,
perpetuating a cycle that exacerbates kidney fibrosis and a decline of renal function. Multiple RAS
genes are direct targets of Wnt/β-catenin signaling [44].
However, to date, there is no evidence showing the relationship between Klotho reduction and
PRR expression. Given that CKD and Wnt/β-catenin signaling regulate PRR expression, and FGF23
enhances sodium reabsorption through sodium/chloride cotransporter in the distal tubule [45,46],
it can be hypothesized that increased FGF23, Wnt activation, and the downregulation of Klotho in
CKD may promote volume overload and an elevation in blood pressure, two well-known risk factors
for heart failure. Nevertheless, this remains speculative and requires further investigation. Therefore,
FGF23, Klotho, and the Wnt pathway may have relevance in the control of blood pressure and RAS.
4.2. FGF23/Klotho and Cardiac Hypertrophy
An increase in the FGF23/Klotho ratio is present since the early stages of CKD, and it is associated
with CVD, especially with LVH [47] and vascular calcification [48,49]. Studies by Myles Wolf’s group
demonstrated that high levels of FGF23 caused LVH [50]. It is reasonable to speculate that FGF23
through a Wnt signaling activation might be a cause of LVH. In the experimental setting, and with
respect to left ventricular remodeling, it is observed that Wnt signaling inhibition improves cardiac
function; sFRP or Disheveled, both Wnt inhibitors, attenuate left ventricular remodeling [51].
Experimental studies have shown a cardioprotective effect of Klotho, although the mechanisms are
unknown. Yu et al. [52] observed that Klotho reduced the Angiotensin II-induced hypertrophic growth
of neonatal cardiomyocytes. In these cells, Angiotensin-II promoted Wnt/b-catenin activation while
Klotho decreased it. Klotho administration also suppressed the expression of Angiotensin-II receptor
type I showing that Klotho might be considered as an antihypertrophic factor useful in heart diseases.
A recent study has shown in hemodialysis patients that higher serum FGF23 and lower sKlotho
and sclerostin (an endogenous Wnt inhibitor) levels were associated with chronic inflammation,
malnutrition, secondary hyperparathyroidism, and may be considered as predictors of cardiovascular
complications, such as LVH, acute coronary syndrome, or rhythm disturbances [53].
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4.3. FGF23–Klotho–Wnt and Cardiac Fibrosis
During cardiac fibrosis some of the evidences showing a crosstalk of FGF23 and Klotho with Wnt
signaling are described. Cardiac fibrosis is characterized as an excessive accumulation of fibroblasts,
myofibroblasts, and extracellular matrix proteins in the myocardium [54]. Human hearts with severe
epicardial fibrosis show increased activation of β-catenin and TCF/LEF [55]. Additionally, TGF-β is a
key profibrotic cytokine in the development of cardiac fibrogenesis. It has been proposed that TGF-β
activates Wnt/β-catenin signaling through the production of Wnt proteins, and by direct deactivation
of GSK3β. Activated Wnt/β-catenin, in turn, stabilizes the TGF-β/Smad response. It appears that
the co-activation of these two pathways is required to trigger the effective fibrotic response [56].
Akhmetshina et al. showed that canonical Wnt signaling activation is required for TGF-β-mediated
fibrosis [57]. Recently, Liu Q et al. showed through in vitro studies that the loss of endogenous cardiac
Klotho in CKD patients, specifically in cardiomyocytes, intensifies TGF-β1 signaling, which enables
more vigorous cardiac fibrosis through upregulation of Wnt signaling. Moreover, the upregulation of
endogenous Klotho inhibited Wnt/β-catenin signaling [58], a desirable strategy for the prevention and
treatment of cardiac fibrosis in CKD patients.
Other authors have shown that secreted Klotho can inhibit TGF-β1 signaling through its interaction
with TGF-β1 cell-surface receptors [59].
With respect to FGF23, Hao et al. observed that in cultured adult mouse cardiac fibroblasts,
rFGF23 increased active β-catenin, procollagen I, and procollagen III expression [60]. Schumacher
et al. showed that FGF23 increased the expression of Collagen 1, MMP8, and fibronectin in cardiac
fibroblasts; in addition, they showed that high levels of FGF23 increased the expression of TGF-β1 in
M2 polarized macrophages [61]. So, FGF23 might be involved also in cardiac fibrosis generation.
These studies reveal a close association between Klotho, TGF-β, and Wnt signaling activation in
the generation of cardiac fibrosis. The evaluation of these parameters in the context of clinical studies
will determine if modulation of Wnt signaling could be a potential therapeutic target.
4.4. FGF23/Klotho and Atherosclerosis
Vascular endothelial dysfunction is one of the first events in the atherosclerotic process.
The endothelial injury allows monocyte adhesion with subsequent infiltration into the subintimal space.
Subsequently, these monocytes are differentiated into macrophages, beginning an inflammatory process
with the release of proinflammatory cytokines and nuclear translocation of NF-kB. This inflammatory
process produces changes in vascular smooth muscle cells (VSMC) from contractile to a synthetic
phenotype with a higher capability to migrate from the media to the intima layer in arteries. In this
space, both macrophages and VSMC accumulate lipids resulting in the formation of an atherosclerotic
plaque with a fibrous cap on the luminal side of the vessel [62].
The atherosclerotic process is also associated with Wnt signaling activation. There is a positive
correlation between the severity of the atherosclerotic lesion and serum Wnt5a levels. Moreover, Wnt5a
staining has been detected in intimal areas of macrophage accumulation in atherosclerotic lesions
of apolipoprotein-deficient mice, and human endarterectomy samples. Christman et al. showed
that oxidized LDL induced Wnt5a expression, a potential mechanism to activate Wnt signaling
(Figure 2) [63]. Other authors have shown that elevated concentrations of oxidized LDL induce a
decrease in renal Klotho expression [64].
Similarly, in human umbilical vein endothelial cell (HUVEC), recombinant Klotho supplementation
can attenuate oxidized-LDL-induced oxidative stress through upregulating oxidative scavengers (SOD
and NO) [65]. Certainly, more studies are necessary to confirm the potential interaction between
oxidized LDL, Klotho, Wnt, and atherosclerosis progression.
In a recent publication, we have reported a significant association between FGF23 levels and
carotid intimal media thickness. In 939 subjects with coronary heart disease without CKD enrolled
in the CORDIOPREV study, we found that FGF23 was independently associated with intima-media
thickness of both common carotid arteries [66].
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Chen et al. observed that in hemodialysis patients, sclerostin was also positively associated
with carotid intima-media thickness, and patients with low baseline serum sclerostin displayed a
better survival. Interestingly, in this study, the authors found a negative association of sclerostin with
sKlotho [67]. Although in these patients, low sKlotho levels are caused by the advanced state of CKD,
it is unknown if low sKlotho levels also cause high levels of sclerostin. At the moment, it is unknown
whether FGF23 through the Wnt signaling might promote the atherosclerotic process.
4.5. FGF23/Klotho and Vascular Calcification
Vascular calcifications are common in patients with advanced CKD, and at present, it is responsible
for the high CVD-related mortality [68]. Vascular calcification is the final consequence of a process
where VSMC are transdifferentiated into osteoblast-like cells [69].
Patients with end-stages CKD have an important disbalance of mineral metabolism with high
levels of serum phosphate, which have been associated in vivo, and in vitro, with the generation
of vascular calcification [70]. Different authors and our group have shown that high phosphate
levels can activate Wnt signaling in VSMC [71,72]. Interestingly other studies have shown that
Klotho supplementation may prevent VSMC calcification through inhibition of the Wnt/b-catenin
pathway [73].
We have investigated the relationship between vascular calcification, inflammation, and Wnt
signaling. The administration of lipopolysaccharide (LPS) to healthy rats produced inflammation and
a parallel increase in serum FGF23 levels and a reduction in renal Klotho expression. Subsequently,
ex vivo experiments using slices of kidney tissue showed that LPS and also high phosphate-induced
nuclear translocation of β-catenin and p65-NF-kB, with a decrease in Klotho. Inhibition of both
inflammation and Wnt signaling activation decreased FGF23 levels and increased renal Klotho [74]
(Figure 2). These results support the close relationship between inflammation, impairment in phosphate
regulation, calcification, Klotho, and Wnt signaling.
The potential direct effect of FGF23 on VSMC to promote or inhibit calcification remains
controversial. Some authors have found that FGF23 directly increases VSMC calcifications, while other
authors emphasized that FGF23 is not involved in this process [75–77]. Similarly, it is unknown if
FGF23 might or might not promote changes on the VSMC phenotype, with loss of vascular function,
atherosclerosis, or even arterial stiffness [78].
5. FGF23-Klotho and Wnt in Bone
Historically, the participation of the Wnt/β-catenin pathway in bone disorders has been widely
documented. SOST gene produces sclerostin that modulates the Wnt activity. Without sclerostin,
Wnt activity is unrestricted, producing increased bone mineral density with hyperostosis. Thus, the
canonical Wnt pathway is critical in bone formation, and its modulation could be a target in the
treatment of bone disorders.
In relation to CKD, two inhibitors of the canonical Wnt pathway have been investigated: Dkk1
and sclerostin [79]. Paradoxically, despite both molecules inhibiting the Wnt ligand–LRP5/6–Frizzled
interaction, the downstream responses are different, illustrating the complexity of this pathway.
In CKD patients, the correlation of serum Dkk1 with mineral and bone parameters is nonexistent in
most studies [80,81], suggesting that Dkk1 might have a weak relation with renal osteodystrophy.
Nevertheless, the serum sclerostin levels increase early in CKD before renal osteodystrophy is
established. Sclerostin is produced and secreted by osteocytes, suggesting an essential role in the
relationship between bone, kidney, and Wnt in CKD patients [82]. Serum sclerostin levels are higher in
males than females, and the levels do not correlate with age. In CKD patients, plasma sclerostin increases
progressively as the glomerular filtration rate declines, and it correlates with serum phosphate [83].
The cause of increased plasma levels of sclerostin in CKD patients is unknown. Osteocytes produce
sclerostin, and VSMC transdifferentiated into osteoblast in calcified vessels. Likewise, there is limited
information about the relationship between sclerostin levels and bone in CKD. Paradoxically, there
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is a positive association between serum sclerostin levels and bone mineral density in hemodialysis
patients [84]. Additionally, the administration of neutralizing antibodies against sclerostin in a murine
model of CKD resulted in beneficial only in low PTH conditions [85].
There are many questions in relation to sclerostin and CKD that remain to be answered. It is
unknown if high levels of sclerostin protect against vascular calcification where Wnt/b-catenin promotes
osteogenic transdifferentiation of VSMC; it is also unclear to what extent high sclerostin affects bone
turnover and renal osteodystrophy. The relationship between sclerostin and other mineral metabolism
parameters, such as PTH, FGF23, vitamin D, or Klotho, is also unclear. Perhaps more studies are
necessary to characterize the effects of Wnt activity on bone metabolism in CKD.
With respect to FGF23, Carrillo et al. identified that FGF23 directly inhibits Wnt signaling through
the increase of Dkk1 levels. This action occurs in bone with the participation of soluble Klotho
(sKlotho) [86]. This work provides evidence of the autocrine effects of FGF23, which could contribute
to the generation of renal osteodystrophy (Figure 2). These results would be aligned with those
indicating that an increase of sclerostin would contribute to the inhibition of osteogenesis. A recent
study has shown a positive correlation between FGF23 and sclerostin levels in patients with rheumatic
arthritis, suggesting a link between FGF23, reduced Wnt activity, and bone demineralization in these
patients [87]. Evenepoel et al. found that sclerostin but not Dkk1 participate in alterations of mineral
metabolism related to CKD [79,81].
In vitro studies have shown an interaction between FGF23, Klotho, and Wnt signaling in bone
cells. The presence of Klotho in osteocytes and osteoblasts [88], suggests that the bone is another target
organ for FGF23. Several studies indicate that Klotho is a negative modulator of bone formation [3].
The mechanisms are not clear, but it is speculated that Klotho allows FGF23 to enhance Dkk1 expression
resulting in inhibition of Wnt signaling and osteogenesis. This hypothesis is supported by previous
observations showing that Wnt activity is increased in Klotho knockout mice [89]. Ma et al. observed
that in UMR-106, a bone cell line, the addition of β-glycerophosphate increased the expression of Wnt
target genes; the co-administration of β-glycerophosphate and sKlotho led to a decrease in FGF23
levels and a reduction in Wnt activation, suggesting that sKlotho could modulate osteogenesis and
FGF23 production [90]. In this line, other authors have observed that secreted Klotho, through the
inhibition of FGFR1 and ERK phosphorylation, can delay human mesenchymal stem cell differentiation
into osteoblasts [91,92] (Figure 2).
6. Wnt and the Central Nervous System
FGF23, FGF receptors (FGFR), and the co-receptor Klotho are also expressed in the central nervous
system. The biological relevance of the FGF23/Klotho system in the brain is uncertain, but there is
some evidence that FGF23 directly acts on hippocampal neurons reducing memory functions and
learning capacity in CKD patients [93,94]. Low serum Klotho levels have been reported to be associated
with cognitive impairment [95]; however, the mechanisms are unknown. Given that Klotho is an
antagonist of endogenous Wnt/β-catenin activity [32], it is reasonable to speculate that if Klotho reduces
Wnt activity, upregulation of Wnt could be associated with cognitive impairment. Klotho-deficient
mouse models rapidly develop cognitive impairment and show some evidence of neurodegeneration.
In humans, there are reports showing a correlation between Klotho deficiency with dementia and
Alzheimer’s [96]. Different explanations may support this association. First, both FGF23 increase and
Klotho deficiency are associated with a vascular disease, which may cause cognitive deterioration
because based on vascular dysfunction. Second, Vitamin D deficiency is highly prevalent in CKD
patients, and alterations mainly mediate in the FGF23/Klotho axis. Vitamin D deficiency has also
been related to cognitive decline in older adults. Third, Klotho plays a critical role in life-extension by
regulating telomere length and telomerase activity. Both Klotho and telomeres regulate the stem cell
aging process through Wnt signaling [97] (Figure 2). Klotho deficiency results in continuous activation
of Wnt signaling and senescence of stem cells [98]. Long-lasting activation of Wnt signaling may
cause rapid exhaustion and depletion of neural stem cells. Since stem cell dysfunction limits tissue
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regeneration and potentially affects aging processes, the ability of secreted Klotho protein to inhibit
Wnt signaling may reduce aging-like phenotypes in Klotho-deficient mice. Li et al. have shown that
Klotho improves memory performance but disturbs some aspects of social behavior [99]. This has been
proven in in vivo experiments, in which the addition of only the secreted Klotho protein improves
the learning and memory capabilities of old animals [100]. Klotho is also being considered a new
therapeutic target of neurodegenerative diseases [101]. Since CKD patients have an increase of FGF23
and a reduction of vitamin D and Klotho levels, it could be hypothesized that CKD patients may also
show a decrease in the production of cerebral Klotho, which would upregulate Wnt signaling and
produce the cognitive dysfunction frequently observed in these patients.
7. FGF23/Klotho and Wnt in Other Organs
In the lungs, low Klotho may contribute to the development of idiopathic pulmonary fibrosis [102].
The co-administration of Klotho with rFGF23 reduced fibrosis and inflammation through the inhibition
of the TGF-β signaling and the decrease in SMAD3 phosphorylation. Klotho relevance on pulmonary
disease is reinforced by recent evidence suggesting that less circulating Klotho correlates negatively
with lung function parameters, such as the forced vital capacity (FVC), the forced expiratory volume in
1 s (FEV1), and the diffusing capacity of the lung for carbon monoxide (DLCO) [102,103].
Chronic obstructive pulmonary disease (COPD) is associated with the downregulation of Klotho
expression in the airways and an increase in circulating FGF23 levels [104]. Oxidative stress produced
by cigarette smoking may be responsible for Klotho deficiency in such a population. Moreover, COPD
patients also show elevated inflammatory parameters that may increase FGF23 production, which in
turn induce the expression of locally secreted IL-1β in bronchial epithelial cells [105]. Interestingly,
the instillation of sKlotho protects bronchial epithelial cells from the pro-inflammatory actions associated
with cigarette smoke and FGF23 [105]. Nevertheless, the precise mechanisms whereby pulmonary
Klotho expression is downregulated remain undefined. Wnt/β-catenin signaling has recently gained
relevance after the demonstration of enhanced noncanonical Wnt-5a activation in human fibroblasts
from COPD patients, causing enlargement and destruction of alveolar space and contributing to
emphysema development [106]. The inhibition of the Wnt-5a pathways in the lung helps to recover
alveolar cell functions, perhaps through the regulation of TGF-β activity by Wnt-5a [107]. Upregulation
of Wnt signaling is also associated with an increment in pulmonary vascular resistance, leading to the
development of pulmonary arterial hypertension [41]; upregulation of the Wnt/β-catenin pathway has
been associated with the proliferation of pulmonary artery smooth muscle cells, pulmonary artery
resistance, and heart failure.
Our opinion is that the evidence is limited, and further investigation to define whether deficiency
of lung Klotho and Wnt/β-catenin signaling plays a role in pulmonary fibrosis and emphysema
is required.
Concerning the liver, a specific effect of α-Klotho in the liver is only partially defined. To date,
there is no evidence of a detrimental effect of the FGF23/Klotho complex in the liver. In fact, FGF23
promotes hepatocytes proliferation and cytokine production [94,108], despite the lack of expression of
Klotho in hepatocytes [94]. Thus, FGF23 action on the liver is Klotho independent, and it is mediated
by FGFR4 [46,108]. The Wnt/β-catenin, together with different FGFs, are pivotal in hepatobiliary
development; early in embryonal development, β-catenin warrants hepatoblast proliferation and
conversion into hepatocytes [109].
The liver is tightly associated with multiple endocrine functions, such as energy homeostasis.
In this line, it seems that sKlotho improves insulin sensitivity and insulin release, and it reduces lipid
accumulation in the liver [110]. Reciprocally, β-Klotho likely preserves liver integrity by serving as
co-receptor for endocrine FGF21, a liver-derived hormone and member of the FGF family that promotes
thermogenesis and glucose uptake in adipose tissue [111]. Chronic liver injuries frequently evolve
liver fibrosis with a loss of function. There is data suggesting that the Wnt/β-catenin pathway is the
main regulator of liver fibrosis. Both Wnt-5a and TGF-β are related to myofibroblast proliferation,
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collagen deposition, and fibrosis of the liver [41,112]. Nonetheless, dysregulation of Klotho has not
been identified as responsible for liver fibrosis.
In summary, a consequence of the deterioration of kidney function is the modification of regulatory
systems in an attempt to restore homeostasis. However, the “price to pay” is that these adaptations
may disrupt the physiology, and comorbidities may become apparent. The Wnt/β-catenin cell
signaling pathway has gained attention, given the demonstrated role in the development of different
CKD-associated comorbidities. Phosphate overload downregulates renal Klotho expression through
the activation of the Wnt/β-catenin signaling pathway, thus contributing to the development of vascular
calcification and the alteration of the regulation of mineral metabolism.
The activation of Wnt/β-catenin has other consequences; it promotes tissue fibrosis in both kidney
and heart and, more importantly, the upregulation of Wnt/β catenin may facilitate the crosstalk
between the heart and kidney playing a critical role in the development of the cardiorenal syndrome.
It is important to note that activation of FGF23/Klotho/Wnt signaling correlates with the severity of
atherosclerotic plaques, carotid intimal media thickness, and VSMC calcification. As such, the current
evidence suggests that Wnt/β-catenin activation plays an essential role in CKD progression and
cardiovascular disease. Therefore, the Wnt/β-catenin pathway may deserve future evaluation as a
potential therapeutic target aiming to reduce the prevalence of CKD-associated comorbidities.
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FGF23 Fibroblast Growth Factor 23
CKD Chronic kidney disease
FGFR1 Fibroblast Growth Factor Receptor-1
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Dkk1 Dickkopf-related protein-1
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sFRP Secreted Frizzled-Related Protein
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HUVEC Human Umbilical Vein Endothelial Cell
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